Avedro, Inc.: Series C $25M

Posted in I - Series C, Q - 3Q11, R - NORTH EAST, X - Device (Ophthalmology), X - Opthalmology, XX - MA

Averdo (Waltham, MA) a commercial-stage ophthalmology medical device company focused on procedures for biomechanically strengthening and modifying the cornea, closed on $25M Series C financing. Participants include SCP Vitalife, Aperture Venture Partners, Prism VentureWorks, De Novo Ventures, Flagship Ventures, Borealis Ventures and Echelon Ventures.
Thanx for your patience as we catch-up.

Sep

2011

Simpirica Spine, Inc.: Series B $22M

Posted in I - Series B, Q - 3Q11, R - WEST, X - Device (Spine), XX - CA

Simpirica Spine (San Carlos, CA) a clinical-stage medical device company focused on minimally invasive, flexion-restricting lumbar stabilization devices, closed a $22M Series B financing. Participants include Norwest Venture Partners, De Novo Ventures and U.S. Venture Partners.

May

2010

Astute Medical, Inc.: Series B $26.5M

Posted in I - Series B, Q - 2Q10, R - WEST, X - Device (Diagnostic), X - Pain, X - Sepsis, XX - CA

Astute Medical (San Diego, CA) a development-stage diagnostic company focused on the identification and validation of protein biomarkers that can test for hospital acquired acute conditions like sepsis, kidney injury and abdominal pain, closed a $26.5M Series B financing. Participants include Domain Associates, Delphi Ventures, Johnson & Johnson Development Corp. and De Novo Ventures.

May

2010

TearScience, Inc.: Series C $44.5M

Posted in I - Series C, Q - 2Q10, R - SOUTH EAST, X - Device (Ophthalmology), XX - NC

TearScience (Morrisville, NC) a clinical-stage medical device company focused on the treatment of chronic evaporative dry eye due to obstructive Meibomian Gland Dysfunction, closed a $44.5M Series C financing. Participants include Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker Bio Ventures.

Apr

2010

HemaQuest Pharmaceuticals, Inc. Series B $12M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Antiviral, X - EBV, X - HIV, X - HPV, X - Hemoglobin, X - Sickle Cell, XX - MA

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

Mar

2010

Pulmonx, Inc.: Series C $32M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Device (COPD), X - Device (Pulmonary), XX - CA

Pulmonx (Redwood City, CA) a commercial-stage medical device company focused on minimally invasive devices for the diagnosis and treatment of COPD and other pulmonary disorders, closed a $32M Series C financing. Participants include HealthCap, Kleiner Perkins Caufield & Byers, De Novo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners and Posco BioVentures.

Jan

2010

Lux Biosciences, Inc.: Series B $50M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Opthalmology, XX - NJ

Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...